Secondary prevention of deep vein thrombosis: current approaches, efficacy and safety
- Autores: Zolotovskaya I.A.1, Shatskaya P.R.1
-
Afiliações:
- Samara State Medical University
- Edição: Volume 32, Nº 6 (2025)
- Páginas: 10-15
- Seção: Cardiology
- URL: https://journals.rcsi.science/2073-4034/article/view/350637
- DOI: https://doi.org/10.18565/pharmateca.2025.6.10-15
- ID: 350637
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
Background: Deep vein thrombosis (DVT) is one of the most significant vascular diseases, often complicated by pulmonary embolism (PE). The high risk of recurrent DVT requires long-term secondary prevention, which dictates the need to select optimal anticoagulant therapy and continuously assess the balance between efficacy and safety.
Objective: Review of current strategies for secondary prevention of DVT, assessment of the risks and benefits of prolonged anticoagulant therapy, with an emphasis on the role of new direct oral anticoagulants (DOACs), in particular rivaroxaban and its generic Xyltess.
Results: An analytical review of current international and domestic clinical guidelines, as well as key prospective studies on secondary prevention of venous thromboembolic complications (VTEC) was conducted. Prolonged DOAC therapy showed the greatest effectiveness in preventing recurrent DVT and other VTEC. Idiopathic DVT, thrombophilia, proximal localization and concomitant oncology require an individualized approach to the duration of therapy. The generic drug rivaroxaban Xyltess is completely bioequivalent to the original, has European quality and improved accessibility for patients.
Conclusion: Prolonged secondary prevention of DVT using modern DOACs allows achieving an optimal balance of benefit and safety, reducing the risk of relapse and improving long-term clinical outcomes in most categories of patients.
Palavras-chave
Texto integral
##article.viewOnOriginalSite##Sobre autores
Irina Zolotovskaya
Samara State Medical University
Autor responsável pela correspondência
Email: i.a.zolotovskaya@samsmu.ru
Dr. Sci. (Med.), Head of the Department of Scientific and Innovative Technologies in Healthcare, Associate Professor at the Department of Hospital Therapy with Courses in Hematology and Transfusiology
Rússia, SamaraPolina Shatskaya
Samara State Medical University
Email: polya.sha98@gmail.com
ORCID ID: 0000-0001-5183-1208
Teaching Assistant at the Department of Propaedeutic Therapy with Course in Cardiology
Rússia, SamaraBibliografia
- Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. URL: https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
- Duffett L., Castellucci L..A, Forgie M.A. Risk of Recurrent Venous Thromboembolism in Patients Discontinued from Anticoagulant Therapy. J Thromb Thrombolysis. 2021;51(1):1–7. URL: https://pubmed.ncbi.nlm.nih.gov/33533406/
- ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2024). URL: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism
- Rigatelli G., Zuin M., Roncon L. Long-Term Risk and Secondary Prevention of Deep Vein Thrombosis. Life (Basel). 2023;13(6):1171. URL: https://www.mdpi.com/2075-1729/13/6/1171
- Rodgers G.M, et al. Management of Venous Thromboembolism: Historical Perspectives, Treatment and Future Directions. J. Blood Med. 2023;14:145–164. URL: https://www.dovepress.com/management-of-venous-thromboembolism-historical-perspectives-treatment-peer-reviewed-fulltext-article-JBM
- Palareti G., Cosmi B, Legnani C. D-dimer testing to determine the duration of anticoagulation after unprovoked venous thromboembolism: an updated review. Int J Lab Hematol. 2022;44(2):219-229. URL: https://onlinelibrary.wiley.com/doi/10.1111/ijlh.13750
- Weitz J.I., Lensing A.W., Prins M.H., et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376:1211–1222. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1700518
- Кривощеко ЕП, Мигунов ИА. Современный подход в лечении острого тромбоза глубоких вен нижних конечностей. Практическая ангиология. 2015;19(2):35-41. [Krivosheko EP, Migunov IA. Modern approach to the treatment of acute deep vein thrombosis of the lower extremities. Practical angiology. 2015;19(2):35-41. (In Russ.)]. URL: https://www.medicus.ru/prangiology/view/44289
- Российские клинические рекомендации по диагностике и лечению венозных тромбоэмболических осложнений – 2023. [Russian clinical guidelines for the diagnosis and treatment of venous thromboembolic complications – 2023. (In Russ.)]. URL: https://medi.ru/klinicheskie-rekomendacii/venoznye-tromboembolicheskie-oslozhneniya_14273/
- Инструкция по медицинскому применению препарата Ксилтесс (ривароксабан Эгис). [Instructions for medical use of the drug Xiltess (rivaroxaban Egis). (In Russ.)]. URL: https://www.vidal.ru/drugs/xiltex
Arquivos suplementares
